Table 1.

Baseline Characteristics

Characteristic	Parameter	Value
Sex	Female	47 (35.9%)
	Male	84 (64.1%)
Age, y		59 ± 1
ECOG performance status	0	74 (64.9%)
	1	33 (29.0%)
	2	6 (5.3%)
	3	1 (0.9%)
Site	Medical center 1	43 (32.8%)
	Medical center 2	88 (67.2%)
CEA, ng/mL		37.3 (0–7690.5)
ALT, IU/L		33.5 (10–291)
AST, IU/L		39 (13–207)
ALP, IU/L		138 (43–1,554)
Albumin, g/dL		3.9 (2.6–4.7)
Bilirubin, mg/dL		0.5 (0.2–2.9)
NLR class	1	81 (64.3%)
	2	45 (35.7%)
Extrahepatic metastases	Yes	59 (46.1%)
	No	69 (53.9%)
Lesion size, cm		<5 (1.5–20.8)
Tumor volume, %		12.6 (0.8–76.0)
Metastasis to liver	Synchronous	94 (71.8%)
	Metachronous	37 (28.2%)
Lesion category	Dominant	35 (27.1%)
	Diffuse	94 (72.9%)
Previous chemotherapy lines	0	2 (1.6%)
	1	39 (30.5%)
	2	50 (39.1%)
	3	22 (17.2%)
	≥4	15 (11.7%)
Hepatic local therapy	Yes	34 (26.0%)
	No	97 (74.0%)
Hepatic regional therapy	Yes	43 (32.8%)
	No	88 (67.2%)
Type of hepatic locoregional therapy*	Resection	18 (13.7%)
	Transarterial chemoembolization	10 (7.6%)
	Cryoablation	2 (1.5%)
	HAIP	2 (1.5%)
	RFA	16 (12.2%)
	SBRT	4 (3.0%)
Primary colorectal cancer removal	Yes	104 (79.4%)
	No	27 (20.6%)
Side of origin of primary colorectal tumor	Left	89 (67.9%)
	Right	25 (19.1%)
	Unknown	21 (16.0%)
Lung shunting, %		4 (0–18)
Treatment approach	Sequential lobar	67 (51.1%)
	Single administration	64 (48.9%)
Radiation activity, GBq		1.51 ± 0.04

Note–Values are presented as n(%), mean ± SD, or median (range). ALP = alkaline phosphatase; ALT = alanine transaminase; AST = aspartate transaminase; CEA = carcinoembryonic antigen; ECOG = Eastern Cooperative Oncology Group; HAIP = hepatic artery infusion pump; NLR = neutrophil-lymphocyte ratio; RFA = radiofrequency ablation; SBRT = stereotactic body radiotherapy.

^*Some patients underwent more than one type of hepatic locoregional therapy.